NUV-655 is under clinical development by Nuvalent and currently in Phase II for Papillary Thyroid Cancer. According to GlobalData, Phase II drugs for Papillary Thyroid Cancer have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NUV-655’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NUV-655 is under development for the treatment of solid tumor, non-small cell lung cancer (NSCLC), cholangiocarcinoma, neuroblastoma, anaplastic large cell lymphoma, diffuse large b-cell lymphoma, esophageal squamous cell carcinoma, renal cell carcinoma, breast cancer, inflammatory myofibroblastic tumor (IMT), colorectal cancer, ovarian cancer, papillary thyroid cancer and soft-tissue sarcoma. It acts by targeting anaplastic lymphoma kinase (ALK). It is administered through oral route.
Nuvalent is a biopharmaceutical company that discovers and develop novel drug candidates to treat cancer. It investigates its pipeline programs including NVL-520, a novel brain-penetrant ROS1-selective inhibitor; and NVL-655, an ALK-selective inhibitor for the treatment of non-small cell lung cancer (NSCLC). It is also evaluating multiple discovery-stage research programs in the area of oncology. Nuvalent develop small molecules to minimize adverse events and address brain metastases. The company works in collaboration with medical institutions, CROs and CMOs to conduct and support preclinical studies and clinical trials. Nuvalent is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of NUV-655’s drug-specific PTSR and LoA scores, buy the report here.